CANNASIGNAL™
LIVE DATA
🔍
SIGNAL
HEMP BAN: Federal intoxicating-hemp ban takes effect Dec 11, 2026 — consumer migration to licensed markets expectedFEDERAL: Schedule III rescheduling in progress — 280E relief expected late 2026FEDERAL RISK INDEX: 37/100 (LOW) — rescheduling momentum growingVA: Adult-use retail launches Jul 1, 2027 — license applications open Feb 1, 2027IL: SB 3222 omnibus signed — possession limits doubled, intoxicating hemp moves to dispensaries Nov 12MI: 24% wholesale tax challenged in court — repeal bill SB 810 pending in committeeCA: Cannabis excise tax locked at 15% through July 2028 per AB 564NJ: Cannabis consumption lounges now open in Atlantic City, Newark, MerchantvilleMN: Omnibus Cannabis Act signed — hemp-to-cannabis license bridge ahead of federal banOK: Governor pushes to eliminate medical program — bipartisan opposition buildingHEMP BAN: Federal intoxicating-hemp ban takes effect Dec 11, 2026 — consumer migration to licensed markets expectedFEDERAL: Schedule III rescheduling in progress — 280E relief expected late 2026FEDERAL RISK INDEX: 37/100 (LOW) — rescheduling momentum growingVA: Adult-use retail launches Jul 1, 2027 — license applications open Feb 1, 2027IL: SB 3222 omnibus signed — possession limits doubled, intoxicating hemp moves to dispensaries Nov 12MI: 24% wholesale tax challenged in court — repeal bill SB 810 pending in committeeCA: Cannabis excise tax locked at 15% through July 2028 per AB 564NJ: Cannabis consumption lounges now open in Atlantic City, Newark, MerchantvilleMN: Omnibus Cannabis Act signed — hemp-to-cannabis license bridge ahead of federal banOK: Governor pushes to eliminate medical program — bipartisan opposition building
SD HB1099Passedas of 2026-03-10

Reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Plain-English summary

What happened: A South Dakota bill signed into law on March 10, 2026 reschedules FDA-approved crystalline polymorph psilocybin drug products from Schedule I to Schedule IV.

Why it matters: Rescheduling FDA-approved psilocybin to Schedule IV creates a legal framework in South Dakota for dispensing and testing that pharmaceutical product, affecting licensed pharmacies, labs, and potentially medical providers.

Affects: labs and retailers

LATEST ACTION: Signed by the Governor on March 10, 2026 H.J. 547
READ THE FULL BILL TEXT →
Follow South Dakota cannabis bills for free. One plain-English email a week with every bill that moved, including this one.
Get the free digest
More South Dakota cannabis bills
SB39Revise provisions relating to industrial hemp.PassedHB1160Repeal the medical marijuana oversight committee.In CommitteeHB1065Revise the medical purpose affirmative defense in cannabis prosecution.In CommitteeHB1255Require that the Department of Health accept the medical records of a veteran applying for a medical cannabis registry identification card.IntroducedHB1211Create a digital registry identification card for medical cannabis patients.IntroducedSB194Limit the potency of cannabis products sold at medical cannabis dispensaries.IntroducedSB181Cause the repeal of the medical cannabis chapter upon the federal re-scheduling of cannabis.IntroducedSB143Require that the Department of Health annually report on public health effects of cannabis use.Introduced
ALL SOUTH DAKOTACANNABIS LAWS & BILLS →

Legislative data via LegiScan, licensed under CC BY 4.0. Summaries and categorization by CannaSignal. Regulatory information, not legal advice.